Novavax (NVAX) Interest Coverage Ratio (2010 - 2026)
Novavax (NVAX) recorded quarterly Interest Coverage Ratio of 3.15 in Q1 2026, down 228.85% quarter-over-quarter from 2.44 in Q4 2025, and down 103.5% on a YoY basis from 90.08 in Q1 2025.
Novavax (NVAX) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Novavax's Interest Coverage Ratio history runs 17 years deep, the most recent figure standing at 3.15 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 103.5% year-over-year to 3.15; the TTM figure through Mar 2026 stood at 3.6 (down 118.96% YoY), while the FY2025 annual figure was 20.08, up 261.95% from the prior year.
- Interest Coverage Ratio was 3.15 for Q1 2026 at Novavax, down from 2.44 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 90.08 in Q1 2025 to a low of 77.47 in Q2 2022.
- Historically, Interest Coverage Ratio has averaged 13.61 across 5 years, with a median of 30.51 in 2022.
- The sharpest annual moves came in 2023 and 2025: Interest Coverage Ratio plunged 268.83% in 2023, then jumped 355.68% in 2025.
- A 5-year view of Interest Coverage Ratio shows it stood at 53.01 in 2022, then advanced by 15.88% to 44.59 in 2023, then soared by 61.24% to 17.28 in 2024, then jumped by 114.14% to 2.44 in 2025, then plunged by 228.85% to 3.15 in 2026.
- The last three Interest Coverage Ratio figures came in at 3.15 (Q1 2026), 2.44 (Q4 2025), and 32.47 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Novavax | 1.49 Bn | 931.98 Mn | 108.82 Mn | -3.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.15 |
| Dec 31, 2025 | 2.44 |
| Sep 30, 2025 | -32.47 |
| Jun 30, 2025 | 18.32 |
| Mar 31, 2025 | 90.08 |
| Dec 31, 2024 | -17.28 |
| Sep 30, 2024 | -31.64 |
| Jun 30, 2024 | 38.86 |
| Mar 31, 2024 | -35.23 |
| Dec 31, 2023 | -44.59 |
| Sep 30, 2023 | -43.94 |
| Jun 30, 2023 | 17.75 |
| Mar 31, 2023 | -72.47 |
| Dec 31, 2022 | -53.01 |
| Sep 30, 2022 | -30.51 |
| Jun 30, 2022 | -77.47 |
| Mar 31, 2022 | 42.92 |
| Dec 31, 2021 | -160.56 |
| Sep 30, 2021 | -59.27 |
| Jun 30, 2021 | -57.95 |